author-photo

Boro Dropulic

Miltenyi Biotec

38

Papers

966

Citations

Citation Trend

Filter By

Papers (23) Sort By

Journal Conference Others

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma

2021 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Trispecific CD19-CD20-CD22–targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models

2021 Science Translational Medicine
Show All
- Source
- Cite
- Save
Citations (16)
Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells.

2021 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (1)
Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Development of a closed system process for purifying naive CD8+ cells, culturing and transducing with a CD19/22 chimeric antigen receptor (CAR) to produce a clinical T memory stem cell product directed against B cell malignancies

2020 Cytotherapy
Show All
- Source
- Cite
- Save
Citations (1)
On Site Manufacture of AntiCD19 CAR-T Cells. Responses in Subjects with Rapidly Progressive Refractory Lymphomas.

2020 Biology of Blood and Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (1)
Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

2020 Blood
Show All
- Source
- Cite
- Save
Citations (1)
CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

2019 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (24)